{
  "catalysts": [
    {
      "ticker": "MAZE",
      "current_price": 44.5,
      "market_cap": "$2.17B",
      "conviction_score": 9,
      "thesis": "High-conviction run-up play ahead of scheduled Phase 2 data readout for MZE829. Stock recently hit all-time highs ($47.47) and pulled back slightly, offering an attractive entry before the binary event.",
      "catalyst_details": "Phase 2 topline data readout for MZE829 (oral APOL1 inhibitor) in kidney disease expected on February 11, 2026.",
      "absorption_status": "Partially Priced. The stock is near ATHs, indicating insider/institutional confidence, but the recent dip from $47.47 to $45.03 suggests some risk-off positioning, leaving room for a breakout if data is positive.",
      "earnings_date": "N/A (Data Readout Focus)",
      "relative_volume": "1.07x (663k vs 617k avg)",
      "stop_loss_trigger": "$39.67 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "15% Probability of Approval (Conservative estimate creates upside surprise potential)",
      "recency_proof": "2026-02-09",
      "risk": "Binary event risk; negative data could cause 30-50% drawdown.",
      "expected_upside": "30% (Target $60+ on positive data) | Target: $54.16",
      "mispricing_evidence": "Recent analyst price target raises to $50 and $60 (Jan 2026) vs current $45.03.",
      "x_sentiment": "High anticipation for renal disease breakthrough.",
      "atr_value": 3.22,
      "calculated_stop_loss": 39.67,
      "calculated_target": 54.16
    },
    {
      "ticker": "CMPX",
      "current_price": 6.49,
      "market_cap": "$1.13B",
      "conviction_score": 7,
      "thesis": "Momentum breakout play driven by anticipation of pivotal trial results in early 2026. Strong relative strength (+35% in 12 weeks) indicates accumulation.",
      "catalyst_details": "Upcoming pivotal study results for tovecimig (anti-DLL4/VEGF-A) in biliary tract cancer expected in Q1 2026.",
      "absorption_status": "Unpriced Momentum. The stock is up 4.82% recently but remains below analyst targets, suggesting the market is just waking up to the data potential.",
      "earnings_date": "2026-02-26",
      "relative_volume": "Normal",
      "stop_loss_trigger": "$5.89 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "N/A",
      "recency_proof": "2026-02-09",
      "risk": "Clinical trial failure risk; regulatory delays.",
      "expected_upside": "25-40% (Target $8-$9) | Target: $7.70",
      "mispricing_evidence": "Trading at $6.52 vs strong momentum and 'Zacks Rank #2 Buy' rating issued Feb 5, 2026.",
      "x_sentiment": null,
      "atr_value": 0.4,
      "calculated_stop_loss": 5.89,
      "calculated_target": 7.7
    }
  ]
}